Hank Fuchs (BioMarin)
January 10, 2022 07:11 AM EST
R&D
Cell/Gene Tx

How durable is durable? Bio­Marin gears up to bring he­mo­phil­ia A gene ther­a­py to FDA again with 2-year da­ta

Amber Tong

A year and a half af­ter a stun­ning re­jec­tion, Bio­Marin says it has the dura­bil­i­ty da­ta the FDA pre­vi­ous­ly re­quest­ed, paving the way for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times